H

Hillevax Inc
NASDAQ:HLVX

Watchlist Manager
Hillevax Inc
NASDAQ:HLVX
Watchlist
Price: 2.09 USD Market Closed
Market Cap: 104.8m USD

Hillevax Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hillevax Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
H
Hillevax Inc
NASDAQ:HLVX
Stock-Based Compensation
$20.8m
CAGR 3-Years
567%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$962m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$886m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
$503m
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$696.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
$1B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
10%
No Stocks Found

Hillevax Inc
Glance View

Market Cap
104.8m USD
Industry
Biotechnology

Hillevax Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2022-04-29. HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The firm's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The firm's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The firm's clinical development plan is focused on infants.

HLVX Intrinsic Value
3.42 USD
Undervaluation 39%
Intrinsic Value
Price
H

See Also

What is Hillevax Inc's Stock-Based Compensation?
Stock-Based Compensation
20.8m USD

Based on the financial report for Dec 31, 2024, Hillevax Inc's Stock-Based Compensation amounts to 20.8m USD.

What is Hillevax Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
567%

Over the last year, the Stock-Based Compensation growth was 53%. The average annual Stock-Based Compensation growth rates for Hillevax Inc have been 567% over the past three years .

Back to Top